MYOV News and Press, Myovant Sciences Ltd. From 07/14/21

BASEL, Switzerland, July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a big quarter for biotech stocks. Biogen (NASDAQ: BIIB ) had a major breakthrough with the approval of its Alzheimer’s vaccine aducanumab, which is sold under the brand name Aduhelm. It mar...

Myovant recently cleared another regulatory binary for relugolix as a treatment for uterine fibroids. On top of the clearance for advanced prostate cancer, Relugolix is now approved for two indications. With COVID abating, you can anticipate relugolix sales to ramp up by multiple ...

In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline Myovant and Pfizer will jointly commercialize MYFEMBREE, with product availability...

According to the FDA website, Myovant Sciences ([[MYOV]] +5.0%) has received the approval for MYFEMBREE (relugolix; estradiol; norethindrone) tablets on priority review.In August, the company announced the FDA acceptance of its marketing application for relugolix combination tablet (relu...

Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery. Management is advancing a broad pipeline of high-risk/high-reward candidates into Phase II studies for a range of movement and psychi...

Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies -- Urovant became a wholly owned subsidiary of Sumitovant and announced the continuation of its Phase 2a study with novel gene ther...

Today, we revisit Myovant Sciences for the first time in more than a year. The company recently inked a huge deal with Pfizer and has some upcoming potential catalysts on the horizon. A full investment analysis is provided in the paragraphs below. For further details see: ...

Myovant Sciences (MYOV) announces that the Committee for Medicinal Products for Human Use ((CHMP)) of the EMA has adopted a positive opinion for approval of RYEQO (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe sympt...

CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe Relugolix combination tablet for uterine fibroids is also under U.S. FD...